Pancreatic Neuroendocrine Tumor Clinical Trial
Official title:
Phase I Study of Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
The purpose of this research study is to find out more about the combination of RAD001 and sorafenib such as the safest dose to use, the side effects it may cause, and if the drug is effective for treating neuroendocrine tumors.
- Since we are looking for the highest dose of the study drug that can be administered
safely without severe or unmanageable side effects in participants that have
neuroendocrine tumors, not everyone who participates in this research study will
receive the same dose of the study drug. The dose the participant will be given will
depend on the number of participants who have been enrolled in the study.
- Each treatment cycle lasts 28 days. Participants will take RAD001 orally once a day in
the morning. Participants will take sorafenib orally twice daily.
- Initially participants will come to the clinic every other week. At these visits
bloodwork will be taken to monitor the participants health. Every 2 months of
treatment, participants will have a CT scan or MRI done to see how the medication is
working.
- Participants will remain on this research study as long as they continue to benefit
from the study medications.
;
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05566093 -
EUS-FNI for Nonfunctional Pancreatic Neuroendocrine Tumors
|
N/A | |
| Completed |
NCT00970970 -
Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease
|
||
| Recruiting |
NCT05568017 -
Neoadjuvant PRRT With Y-90-DOTATOC in pNET
|
Phase 2 | |
| Not yet recruiting |
NCT06024343 -
Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Repair or Reconstruction
|
N/A | |
| Recruiting |
NCT03891784 -
Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
|
Phase 2 | |
| Recruiting |
NCT03204019 -
A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor
|
Phase 2 | |
| Completed |
NCT00804336 -
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
|
Phase 1 | |
| Recruiting |
NCT05997056 -
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
|
Phase 2 | |
| Not yet recruiting |
NCT06158516 -
A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
| Recruiting |
NCT04119024 -
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05040360 -
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
| Completed |
NCT00576680 -
RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05610826 -
Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03074513 -
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
|
Phase 2 | |
| Completed |
NCT03967951 -
CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms
|
||
| Completed |
NCT01024387 -
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
| Not yet recruiting |
NCT03435770 -
Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms
|
N/A | |
| Recruiting |
NCT04134832 -
Study of Pancreatic Neuroendocrine Tumors and Carcinomas in Alsace Region
|
||
| Recruiting |
NCT05554744 -
EUS-FNI for MEN1-related Pancreatic Neuroendocrine Tumors
|
N/A | |
| Completed |
NCT02159989 -
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
|
Phase 1 |